Cerdulatinib

Protocol Number: Portola — NCT01994382 (http://www.clinicaltrials.gov)
A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib in Patients with Relapsed/Refractor Chronc Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma. – OPEN TO ENROLLMENT